MGMaría Gordillo-Marañón

María Gordillo-Marañón

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Gordillo-Marañón has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score

    by María Gordillo‐Marañón, Cristina Fernández‐Fernández

    Purpose: Follow‐up questionnaires (FUQs) are routinely used in pharmacovigilance to gather further information on suspected adverse drug reactions (ADRs) and are frequently included within Risk Management Plans. However, despite their extensive use and regulatory relevance, their contribution to improving the quality and completeness of case reports has not previously been evaluated quantitatively. The objective of this study was to assess whether the recommendation to implement or discontinue a FUQ was associated with changes in the completeness of information in case reports. Methods: The minutes from January 2018 to July 2025 from the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) were screened to identify recommendations regarding FUQ implementation or discontinuation. For active substance‐ADR combinations associated with a FUQ recommendation, case reports and a standardised measure of report completeness were obtained from EudraVigilance and VigiBase, the WHO global database of adverse event reports for medicines and vaccines, respectively. Interrupted time series analyses were conducted to assess the effect of specific FUQs on the quality of case reporting. Results: Across the 27 active substance‐ADR combinations evaluated, the impact of FUQs on report completeness was heterogeneous. Only six combinations showed statistically significant trend changes, of which one demonstrated a small improvement in completeness after FUQ implementation and five showed declining trends following implementation ( n = 1) or discontinuation ( n = 4). Conclusions: The present findings do not support a consistent association between FUQ implementation and improved case completeness. Other factors, including ADR‐related characteristics and heterogeneity in pharmacovigilance data collection practices, may be more important determinants of report quality. These findings provide the first quantitative evidence on FUQ effectiveness and support a more evidence‐based approach to their evaluation within pharmacovigilance systems.

  • Open Access

    Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases

    by Oskar Rachwal, Mar Gutiérrez-Lobón, Nuria Sols Cueto, Araceli Nuñez Ventura, Cristina Fernández-Fernández, Florence P. A. M. van Hunsel, Joep H. G. Scholl, María Gordillo-Marañón, Eugène P. van Puijenbroek

    Background The COVID-19 mass vaccination led to a substantial increase in spontaneous reports submitted to pharmacovigilance (PV) databases, potentially introducing masking effects that could conceal safety signals. Objectives To examine the masking effect of COVID-19 vaccines on disproportionality analyses and to compare two unmasking interventions in the Dutch (Lareb database) and Spanish (Farmacovigilancia Española, Datos de Reacciones Adversas, FEDRA) national PV databases: removal of all drug–event combinations (DEC) involving a COVID-19 vaccine versus excluding influential outliers DECs only. Methods The masking effect was explored retrospectively on the basis of the number of signals of disproportionate reporting (SDR). DECs involving a COVID-19 vaccine were excluded using crude and outlier techniques, and reporting odds ratios were recalculated. Subsets of important medical events (IME) were analysed in both databases. Results Both crude and influential outlier removal methods led to reductions in the number of reports, DECs and SDRs. Both in the Lareb database and FEDRA, crude removal excluded 2.1% of DECs, while the outlier method excluded 0.1%. Crude removal had a greater impact on SDRs, reducing them by 9.8% in the Lareb database and 3.9% in FEDRA, compared with 5.7% and 1.1% with the outlier method. In the Lareb database, 1301 SDRs (20 IME-related) were unmasked using crude removal, and 1942 (95 IME-related) with the outlier method. FEDRA showed 1453 and 1226 SDRs unmasked, including 41 and 70 IME-related. Conclusions COVID-19 vaccines caused substantial masking in both databases. Both strategies effectively revealed new SDRs, though their impact varied. The choice of approach should be tailored to the database context.


  • Open Access

    Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes

    by Marta Alcalde-Herraiz, JunQing Xie, Danielle Newby, Clara Prats, Dipender Gill, María Gordillo-Marañón, Daniel Prieto-Alhambra, Martí Català, Albert Prats-Uribe

    Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety remains unclear. We conducted a cis-Mendelian randomisation analysis to estimate the causal effect of sclerostin levels on cardiovascular risk factors. We meta-analysed three GWAS of sclerostin levels including 49,568 Europeans and selected 2 SNPs to be used as instruments. We included heel bone mineral density and hip fracture risk as positive control outcomes. Public GWAS and UK Biobank patient-level data were used for the study outcomes, which include cardiovascular events, risk factors, and biomarkers. Lower sclerostin levels were associated with higher bone mineral density and 85% reduction in hip fracture risk. However, genetically predicted lower sclerostin levels led to 25–85% excess coronary artery disease risk, 40% to 60% increased risk of type 2 diabetes, and worse cardiovascular biomarkers values, including higher triglycerides, and decreased HDL cholesterol levels. Results also suggest a potential (but borderline) association with increased risk of myocardial infarction. Our study provides genetic evidence of a causal relationship between reduced levels of sclerostin and improved bone health and fracture protection, but increased risk of cardiovascular events and risk factors.


  • Open Access

    Disease coverage of human genome-wide association studies and pharmaceutical research and development

    by María Gordillo-Marañón, Amand F. Schmidt, Alasdair Warwick, Chris Tomlinson, Cai Ytsma, Jorgen Engmann, Ana Torralbo, Rory Maclean, Reecha Sofat, Claudia Langenberg, et al.

    Background: Despite the growing interest in the use of human genomic data for drug target identification and validation, the extent to which the spectrum of human disease has been addressed by genome-wide association studies (GWAS), or by drug development, and the degree to which these efforts overlap remain unclear.Methods: In this study we harmonize and integrate different data sources to create a sample space of all the human drug targets and diseases and identify points of convergence or divergence of GWAS and drug development efforts.Results: We show that only 612 of 11,158 diseases listed in Human Disease Ontology have an approved drug treatment in at least one region of the world. Of the 1414 diseases that are the subject of preclinical or clinical phase drug development, only 666 have been investigated in GWAS. Conversely, of the 1914 human diseases that have been the subject of GWAS, 1121 have yet to be investigated in drug development.Conclusions: We produce target-disease indication lists to help the pharmaceutical industry to prioritize future drug development efforts based on genetic evidence, academia to prioritize future GWAS for diseases without effective treatments, and both sectors to harness genetic evidence to expand the indications for licensed drugs or to identify repurposing opportunities for clinical candidates that failed in their originally intended indication.


  • Open Access

    Harnessing confounding and genetic pleiotropy to identify causes of disease through proteomics and Mendelian randomisation – ‘MR Fish’

    by Alasdair N Warwick, Aroon D Hingorani, Anthony P Khawaja, María Gordillo-Marañón, Abraham Olvera-Barrios, Kelsey V Stuart, Catherine Egan, Adnan Tufail, Reecha Sofat, Valerie Kuan Po Ai, et al.

    We propose an extension of the Mendelian randomisation (MR) paradigm (‘MR-Fish’) in which the confounded disease association of an index protein (‘the bait’) is harnessed to identify the causal role of different proteins (‘the catch’) for the same disease. Using C-reactive protein (CRP) as the bait, cis -MR analyses refuted a causal relationship of CRP with a wide range of diseases that associate with CRP in observational studies, including type 2 diabetes (T2DM) and coronary heart disease (CHD), suggesting these associations are confounded. Using ‘MR-Fish’, and leveraging large-scale proteomics data, we find evidence of a causal relationship with multiple diseases for several proteins encoded by genes that are trans hits in genome wide association analysis of CRP. These include causal associations of IL6R and FTO with CHD and T2DM; as well as ZDHHC18 with several circulating blood lipid fractions. Among the proteins encoded by genes that are trans -for-CRP we identified 28 that are druggable. Our findings point to a general approach using MR analysis with proteomics data to identify causal pathways and therapeutic targets from non-causal observational associations of an index protein with a disease.


  • Open Access

    Comparing the effects of CETP in East Asian and European ancestries: a Mendelian randomization study

    by Diana Dunca, Sandesh Chopade, María Gordillo-Marañón, Aroon D. Hingorani, Karoline Kuchenbaecker, Chris Finan, Amand F. Schmidt

    CETP inhibitors are a class of lipid-lowering drugs in development for treatment of coronary heart disease (CHD). Genetic studies in East Asian ancestry have interpreted the lack of CETP signal with low-density lipoprotein cholesterol (LDL-C) and lack of drug target Mendelian randomization (MR) effect on CHD as evidence that CETP inhibitors might not be effective in East Asian participants. Capitalizing on recent increases in sample size of East Asian genetic studies, we conducted a drug target MR analysis, scaled to a standard deviation increase in high-density lipoprotein cholesterol. Despite finding evidence for possible neutral effects of lower CETP levels on LDL-C, systolic blood pressure and pulse pressure in East Asians (interaction p-values < 1.6 × 10−3), effects on cardiovascular outcomes were similarly protective in both ancestry groups. In conclusion, on-target inhibition of CETP is anticipated to decrease cardiovascular disease in individuals of both European and East Asian ancestries.


  • Open Access

    Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance

    by Cosimo Zaccaria, Loris Piccolo, María Gordillo-Marañón, Gilles Touraille, Corinne de Vries

    Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.


  • Open Access

    COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance

    by María Gordillo-Marañón, Agnieszka Szmigiel, Vladimíra Yalmanová, Irina Caplanusi, Georgy Genov, David Benee Olsen, Sabine Straus

    Background and Objective During the COVID-19 vaccination campaign, over 34,000 reports of heavy menstrual bleeding following the administration of COVID-19 vaccines originating in the Economic European Area were submitted to EudraVigilance, the European Union database of suspected adverse drug reactions. More than 90% of these reports were sent by consumers while the remaining by healthcare professionals. Public concerns regarding menstruation disorders in COVID-19 vaccinees were also covered by the media. We investigated the impact of media attention on the reporting trends of heavy menstrual bleeding to EudraVigilance. Methods We used media outlets published in the Economic European Area on menstrual disorders and COVID-19 vaccines from the beginning of the vaccination campaign in the Economic European Area (1 January, 2021) until December 2022 (i.e., after the regulatory request to add the adverse event to the product information) and spontaneous reports from EudraVigilance. Results We found that the publication of safety updates from regulatory authorities and subsequent coverage in media outlets preceded increased reporting to EudraVigilance. Furthermore, the heavy menstrual bleeding reported in the cases occurred several weeks or months earlier and were not submitted to the respective date. The analysis suggests that the spikes in reporting of heavy menstrual bleeding were to some extent influenced by media coverage in some countries. Conclusions Consumer reporting to the European Union spontaneous data collection system, EudraVigilance, was of high value for regulatory safety reviews, albeit the reporting behaviours were not free of the influence of the media. These sources of information can be investigated to understand the context of safety concerns of public health interest.


  • Open Access

    Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination

    by María Gordillo-Marañón, Gianmario Candore, Karin Hedenmalm, Kate Browne, Robert Flynn, Loris Piccolo, Aniello Santoro, Cosimo Zaccaria, Xavier Kurz

    During the COVID-19 vaccination campaign, observed-to-expected analysis was used by the European Medicines Agency to contextualise data from spontaneous reports to generate real-time evidence on emerging safety concerns that may impact the benefit-risk profile of COVID-19 vaccines. Observed-to-expected analysis compares the number of cases spontaneously reported for an event of interest after vaccination (‘observed’) to the ‘expected’ number of cases anticipated to occur in the same number of individuals had they not been vaccinated. Observed-to-expected analysis is a robust methodology that relies on several assumptions that have been described in regulatory guidelines and scientific literature. The use of observed-to-expected analysis to support the safety monitoring of COVID-19 vaccines has provided valuable insights and lessons on its design and interpretability, which could prove to be beneficial in future analyses. When undertaking an observed-to-expected analysis within the context of safety monitoring, several aspects need attention. In particular, we emphasise the importance of stratified and harmonised data collection both for vaccine exposure and spontaneous reporting data, the need for alignment between coding dictionaries and the crucial role of accurate background incidence rates for adverse events of special interest. While these considerations and recommendations were determined in the context of the COVID-19 mass vaccination setting, they are generalisable in principle.


  • Open Access

    Comparing the effect profile of cholesteryl ester transfer protein (CETP) in individuals of East Asian and European ancestries

    by Diana Dunca, Sandesh Chopade, Maria Gordillo-Maranon, Aroon Hingorani, Karoline Kuchenbaecker, Chris Finan, Amand Schmidt

    CETP is a lipid drug target under development for coronary heart disease (CHD) in both European and East Asian populations. Previous drug target Mendelian randomization (MR) studies conducted in East Asians failed to show a CHD effect, which has been interpreted as lack of effectiveness of CETP inhibition for CHD prevention in this population. Nevertheless, CETP inhibitors are currently being evaluated in East Asian participants. Capitalizing on recent increases in sample size of East Asian GWAS, we therefore conducted a drug target MR to estimate and compare ancestry-specific effects of on-target CETP inhibition. Employing cross-ancestry colocalization, we found strong evidence of a shared causal CETP variant affecting HDL-C in both populations, which was not observed for LDL-C. WE conducted drug target MR, scaled to a standard deviation increase in HDL-C, and found that lower CETP was associated with lower LDL-C, Lp[a], systolic blood pressure and pulse pressure in both groups, with more pronounced effects in Europeans individuals (interaction p-values < 1.9×10 − 3). Lower CETP was protective against CHD, angina, intracerebral haemorrhage and heart failure in both ancestries, for example for CHD in East Asians (OR 0.89, 95%CI 0.84;0.94) compared to Europeans (OR 0.95, 95%CI 0.92;0.99, interaction p-value = 0.05). In conclusion, on-target inhibition of CETP is anticipated to decrease cardiovascular disease in individuals of both European and East Asian ancestries.